EGFR and colorectal cancer: Recent evidence suggests that patients with left-sided colorectal cancer are associated with favorable clinical benefits from anti-EGFR antibodies as a first-line treatment, and that those with right-sided colorectal cancer are associated with worse clinical benefits [41].